Yeast Beta-Glucan and Mucosal Immunity: What a Small Trial Found

Yeast beta-glucan may help maintain some immune defenses at the surfaces where respiratory viruses first arrive. That is more specific—and more interesting—than the usual "immune support" label. But the evidence comes from one small trial, and its results do not show that beta-glucan raised respiratory antibodies above baseline.

In a 12-week winter trial in healthy Japanese adults, participants taking baker's yeast beta-1,3/1,6-glucan appeared to have smaller declines in secretory immunoglobulin A (sIgA) at the oropharynx and nasopharynx than those taking placebo. The study also reported higher salivary lysozyme, a rise in a blood marker of dendritic-cell maturation, and fewer cumulative upper-respiratory symptom days. Yet the published abstract does not provide the dose, effect sizes, p-values, confidence intervals, or per-group sample sizes. With roughly 40 participants total and several secondary outcomes, this is a hypothesis-generating result—not proof that a supplement strengthens respiratory mucosal immunity.

The finding concerns a frontline barrier, not generic immunity

sIgA helps defend mucosal surfaces, including the nose, throat, and mouth. It differs from antibodies measured in blood: respiratory pathogens encounter mucosal immune defenses before they reach the circulation. Measuring sIgA directly at upper-airway sites is therefore a meaningful methodological choice.

That is what makes the 2026 Kanno et al. randomized, double-blind, placebo-controlled trial worth attention. Over 12 weeks, healthy Japanese adults received baker's yeast-derived beta-1,3/1,6-glucan or placebo. The pre-specified primary endpoint was CD80 expression on circulating classical dendritic cell type 1 cells, a blood-based marker consistent with dendritic-cell maturation. Oropharyngeal and nasopharyngeal sIgA, salivary lysozyme, and upper-respiratory symptom days were secondary endpoints.

The distinction between preservation and elevation matters. The report describes an attenuation of sIgA decline in the beta-glucan group relative to placebo. That could mean the supplement helped maintain seasonal homeostasis. It could also mean that sIgA fell in the placebo group during winter while remaining near baseline in the intervention group. Neither interpretation establishes that beta-glucan actively increased sIgA or that it prevented respiratory infections.

What the trial can—and cannot—tell us

The trial offers the first controlled human signal here for site-specific upper-respiratory mucosal biomarkers after yeast beta-1,3/1,6-glucan. It also reported increased CD80 expression on circulating cDC1 cells at week 8. Because beta-glucans can interact with Dectin-1, a receptor involved in innate immune signaling, the result fits a biologically plausible pathway.

Plausibility is not a completed mechanism. To connect an oral glucan supplement to respiratory sIgA, researchers would need to show more than a change in blood dendritic-cell markers. The proposed chain runs from gut immune recognition to dendritic-cell activation, IgA class switching, and immune-cell trafficking to respiratory tissue. The Kanno trial did not trace that chain in human intestinal or airway tissue.

The missing statistics are the larger problem. Without effect sizes and uncertainty estimates, readers cannot judge how large the reported differences were, whether they were statistically significant, or whether they would matter clinically. The abstract also does not disclose the tested dose, so consumers cannot map the findings to a commercial product.

Small biomarker trials face another predictable problem: multiple comparisons. This study assessed a primary blood endpoint plus several secondary mucosal, salivary, and symptom outcomes. When researchers test several outcomes, some favorable-looking results can arise by chance unless the analysis accounts for that testing burden. The available report does not say whether it did.

The broader beta-glucan literature is more about symptoms than mucosal swabs

A 2021 systematic review by Vlassopoulou et al. found that randomized trials of fungal beta-glucans have commonly measured circulating immune cells and self-reported respiratory symptoms. Across that broader literature, yeast beta-glucan has been associated with fewer self-reported upper-respiratory symptom days in healthy adults.

That evidence supports a narrower, more practical claim: yeast beta-glucan may reduce cold-like symptom burden for some healthy adults. It does not establish that every fungal beta-glucan product works the same way. Fungal beta-glucans vary in source and chemical structure, so favorable findings across the whole category cannot be assigned automatically to baker's yeast beta-1,3/1,6-glucan.

It also does not validate "mucosal-targeted" marketing. Most prior trials did not measure nasopharyngeal or oropharyngeal sIgA. The Kanno study's mucosal measurements are an outlier in the field, not a replicated standard.

Peripheral immune signals do not close the gap

Other human work indicates that baker's yeast beta-glucan can alter immune-related biology outside the airway. In a 2023 study by McFarlin et al., supplementation produced detectable changes in immune-associated mRNA measured from dried blood spots under physical-stressor conditions. That supports a peripheral immunomodulatory signal in stressed people.

It does not show that the supplement changes respiratory sIgA in rested, healthy adults. The endpoints were circulating gene-expression markers, and the observed changes occurred under physical stress. A blood marker can inform a mechanism; it cannot substitute for a patient outcome or prove what happened at the nasal and throat surfaces.

Researchers can measure mucosal immunity in supplementation studies. For example, a 2024 randomized trial of L-glutamine in combat-sport athletes tracked mucosal immune markers after intensive training. That study involved a different supplement, a different population, and a three-week intervention. It demonstrates that sIgA is a usable endpoint, not that L-glutamine confirms beta-glucan's proposed mechanism.

Dose and population questions remain open

There is no usable dose-response answer for respiratory mucosal outcomes. An ongoing Malaysian randomized trial protocol is testing yeast beta-glucan 1,3/1,6 at 120 mg, 204 mg, and a 250 mg comparator dose in moderately stressed adults. Researchers plan to assess respiratory infection incidence, fatigue, immune markers, and gut health. It has no results yet.

The 250 mg/day comparator provides a reasonable research benchmark, not a proven dose for raising respiratory sIgA. The Kanno abstract does not report its dose, which prevents a direct comparison. Its participants were healthy Japanese adults studied during one 12-week winter period; that cannot establish effects across other seasons, ethnic backgrounds, diets, baseline immune states, or microbiomes.

What to do with this evidence

If you already use yeast beta-glucan for upper-respiratory support, the broader symptom-diary literature carries more weight than the mucosal-sIgA claim. The new trial adds an intriguing clue that the compound may preserve upper-airway immune markers during winter. It does not show an absolute sIgA increase, and it does not establish fewer infections through a mucosal mechanism.

A sensible conclusion is modest: yeast beta-1,3/1,6-glucan may help maintain respiratory mucosal markers during winter, but one small exploratory trial cannot confirm that effect or identify the dose that produces it.

The next useful study would be larger, pre-specify respiratory sIgA as a primary endpoint, report effect sizes and confidence intervals, account for multiple outcomes, disclose the dose, and test whether biomarker changes translate into fewer clinically meaningful respiratory infections. Until then, "supports mucosal immunity" is a plausible research hypothesis—not a settled product claim.